China Sets First Global AI BCI Standard
The NMPA has established the first international standard for AI-driven brain-computer interface medical devices, targeting data quality and algorithmic safety.
China’s National Medical Products Administration has approved the world’s first medical device standard for brain-computer interfaces that utilize artificial intelligence. The regulation, reported by Global Times, takes effect on September 1, 2027, and specifically addresses the processing of electrical brain signal data.
This standardization effort is designed to resolve sector-wide inconsistencies in quality control. By defining technical requirements for the entire data-handling pipeline, the NMPA aims to create a unified benchmark for EEG datasets used in the research, development, and production of BCI medical devices.
Standardization of Data Handling Processes
The new framework systematically outlines testing methods for every stage of the BCI data lifecycle. It covers data collection, processing, annotation, storage, and access. This comprehensive approach addresses the lack of standardized dataset development processes that have previously hindered consistent quality control across the industry.
Companies operating in this space will now face a unified quality benchmark for their EEG datasets. This reduces variability in how different manufacturers train their systems, ensuring that the underlying data meets consistent technical and safety criteria before clinical application.
AI Algorithm Training and Safety
The NMPA describes BCI medical devices as intelligent systems that interpret patient intentions by learning from large volumes of EEG data. The quality of this data is critical because it directly determines the accuracy of the AI algorithms and, consequently, the safety of the treatment outcomes for patients.
To support major innovations and meet urgent industry needs, the NMPA used an expedited procedure to initiate and approve this standard. The agency characterizes the new benchmark as being at an internationally leading level, providing a clear regulatory path for AI-enabled medical devices.
Regulatory Timeline and Industry Impact
The standard officially enters into force on September 1, 2027. This timeline provides manufacturers with a defined period to adjust their data collection and annotation protocols to meet the new technical requirements.
By establishing these technical requirements, the NMPA creates a predictable regulatory environment for the BCI sector. This clarity is expected to facilitate further investment and development in AI-enabled medical devices, as companies can now align their internal processes with a recognized national standard.
